On July 14, Kadmon’s stock was at $3.54. However, in today’s pre-market, stock is gaining momentum: it is currently at $4.24, resulting in a 20% gain. The company has recently announced that U.S. Food and Drug Administration (FDA) has approved REZUROCK™ (belumosudil) 200 mg once daily (QD) for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD).
Stephanie Lee, MD, MPH, Professor at the Fred Hutchinson Cancer Research Center, said that patients receiving REZUROCK reported significant boosts in cGVHD symptoms, demonstrating that not only did treatment helped in organ responses, but also improved people overall conditions. This is essential for a chronic disease with a painful symptom hurting.
REZUROCK™ (belumosudil) is the first and only approved therapy targeting Rho-associated coiled-coil kinase 2 (ROCK2), a signaling pathway that modulates inflammatory response and fibrotic processes. REZUROCK is approved in the United States to treat adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy. Kadmon is also developing belumosudil for the treatment of systemic sclerosis. The FDA has granted Orphan Drug Designation to belumosudil for the treatment of systemic sclerosis.
Finance and Entertainment Reporter
Richard is a bottle of wine – the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.